ArticleNature2021
Publisher Correction: A pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction.
Abstract readPublished Erratum
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Viral Dynamic Model-Informed Dose Selection of Mosnodenvir Prophylaxis against DENV-3 in a Controlled Human Infection Model.Clinical pharmacology and therapeutics · 2026Trial
- Therapeutic approaches against dengue virus: current status of vaccines, antivirals, and monoclonal antibodies.Emerging microbes & infections · 2026Review
- A versatile fluorescent reporter for Usutu virus drug screening and infection tracking.PNAS nexus · 2026Article
- Atlastin-2-mediated endoplasmic reticulum membrane tethering is critical for flavivirus replication.PLoS biology · 2026Article
- Synthesis and Evaluation of Aromatic Sulfonamide and Disulfonamide Derivatives as Dengue Virus NS3-NS5 Interaction Inhibitors.ChemMedChem · 2026Article
- In vitro synthesis of active recombinant orthoflavivirus nonstructural polyproteins in detergent micelles for biochemical analysis.Npj viruses · 2026Article
- Cryo-electron tomography reveals coupled flavivirus replication, budding and maturation.Nature communications · 2026Article
- Dengue and severe dengue.Clinical microbiology reviews · 2025Review
- Article
- A Pyrido-Quinoxaline Derivative That Downregulates Reticulon 3 Protein Exhibits Potent Antiviral Activity Against Zika Virus.Journal of medical virology · 2025Article
- Recapitulating dengue virus infection with human pluripotent stem cell-derived liver organoids for antiviral screening.Nature communications · 2025Article
- Viral sepsis - pathophysiology and disease manifestation.Infection · 2025Review
- Modes of action of a small molecule antiviral compound targeting yellow fever virus NS4B protein.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Mechanistic insights into dengue virus inhibition by a clinical trial compound NITD-688.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Article
- Article
- Druggable genome screens identify SPP as an antiviral host target for multiple flaviviruses.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- A Comprehensive Review of the Development and Therapeutic Use of Antivirals in Flavivirus Infection.Viruses · 2025Review
- Dengue Virus Infection: Immune Response and Therapeutic Targets.The American journal of tropical medicine and hygiene · 2025Review
- New dengue virus inhibitors targeting NS3-NS5 interaction identified byFrontiers in microbiology · 2025Article
Corrections and comments
- Erratum for
Authors and funding
24 authors.
Suzanne J F KapteinLaboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-7935-0219
Olivia GoethalsJanssen Global Public Health, Janssen Pharmaceutica, Beerse, Belgium.
Dominik KiemelDepartment of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany.
Arnaud MarchandCistim Leuven, Leuven, Belgium.
Bart KesteleynJanssen Research & Development, Janssen Pharmaceutica, Beerse, Belgium.
Jean-François BonfantiJanssen Infectious Diseases Discovery, Janssen-Cilag, Val de Reuil, France.ORCID http://orcid.org/0000-0002-2107-8857
Dorothée BardiotCistim Leuven, Leuven, Belgium.
Bart StoopsJanssen Research & Development, Janssen Pharmaceutica, Beerse, Belgium.
Tim H M JonckersJanssen Research & Development, Janssen Pharmaceutica, Beerse, Belgium.
Kai DallmeierLaboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-8117-9166
Peggy GeluykensJanssen Research & Development, Janssen Pharmaceutica, Beerse, Belgium.
Kim ThysJanssen Research & Development, Janssen Pharmaceutica, Beerse, Belgium.
Marjolein CrabbeJanssen Research & Development, Janssen Pharmaceutica, Beerse, Belgium.
Laurent Chatel-ChaixDepartment of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-7390-8250
Max MünsterDepartment of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany.
Gilles QueratUnité des Virus Émergents (UVE), Aix-Marseille Univ, IRD 190 Inserm 1207, IHU Méditerranée Infection, Marseille, France.
Franck TouretUnité des Virus Émergents (UVE), Aix-Marseille Univ, IRD 190 Inserm 1207, IHU Méditerranée Infection, Marseille, France.ORCID http://orcid.org/0000-0002-4734-2249
Xavier de LamballerieUnité des Virus Émergents (UVE), Aix-Marseille Univ, IRD 190 Inserm 1207, IHU Méditerranée Infection, Marseille, France.
Pierre RaboissonJanssen Research & Development, Janssen Pharmaceutica, Beerse, Belgium.
Kenny SimmenJanssen Research & Development, Janssen Pharmaceutica, Beerse, Belgium.
Patrick ChaltinCistim Leuven, Leuven, Belgium.
Ralf BartenschlagerDepartment of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-5601-9307
Marnix Van LoockJanssen Global Public Health, Janssen Pharmaceutica, Beerse, Belgium. mvloock@its.jnj.com.ORCID http://orcid.org/0000-0003-4151-4588
Johan NeytsLaboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium. johan.neyts@kuleuven.be.ORCID http://orcid.org/0000-0002-0033-7514
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
PMID
34671169What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.